Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00366899
Other study ID # 6096A1-500
Secondary ID
Status Completed
Phase Phase 3
First received August 17, 2006
Last updated January 17, 2013
Start date October 2006
Est. completion date July 2008

Study information

Verified date January 2013
Source Wyeth is now a wholly owned subsidiary of Pfizer
Contact n/a
Is FDA regulated No
Health authority Italy: Ethics CommitteeUnited States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations in Italy.


Recruitment information / eligibility

Status Completed
Enrollment 605
Est. completion date July 2008
Est. primary completion date July 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 75 Days to 105 Days
Eligibility Inclusion criteria:

1. Aged 3 months (75 to 105 days) at time of enrollment.

2. Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.

3. Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.

4. Born at greater than 32 weeks gestational age and greater than 2000 grams. Regardless of gestational age and birth weight, all subjects must have met inclusion criterion number 3.

5. Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria:

1. Previous vaccination with licensed or investigational pneumococcal vaccine.

2. Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B vaccines.

3. A previous anaphylactic reaction to any vaccine or vaccine-related component.

4. Contraindication to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or hepatitis B, or pneumococcal vaccines.

5. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.

6. Known or suspected immune deficiency or suppression.

7. History of culture-proven invasive disease caused by S pneumoniae or Hib.

8. Major known congenital malformation or serious chronic disorder.

9. Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Did not include resolving syndromes due to birth trauma such as Erb palsy.

10. Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis® [MedImmune]).

11. Participation in another investigational trial. Participation in purely observational studies was acceptable.

12. Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
13-valent pneumococcal conjugate vaccine
Single 0.5 mL dose of 13vPnC given at 3, 5 and 11 months of age.
7 valent pneumococcal conjugate vaccine
Single 0.5 mL dose of 7vPnC given at 3, 5 and 11 months of age.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Wyeth is now a wholly owned subsidiary of Pfizer

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Other Percentage of Subjects Achieving Antibody Titer (OPA) =1:8 in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose Percentage of subjects achieving functional antibody titer =1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. (This is not a geometric mean comparison as suggested by the table row heading). one month after infant series dose 2 and after the toddler dose No
Other Geometric Mean Antibody Titer (OPA) in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay(OPA) for7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. one month after infant series dose 2 and after the toddler dose No
Primary Percentage of Participants Reporting Pre-Specified Local Reactions Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (>7.0 cm). Participants may be represented in more than 1 category. During the 4-day period after each dose Yes
Primary Percentage of Participants Reporting Pre-Specified Systemic Events Systemic events (fever = 37.5 degrees Celsius [C], fever = 38 C but = 39 C, fever >39 C but = 40 C, fever > 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication (meds) to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category. During the 4-day period after each dose Yes
Primary Percentage of Participants Achieving Predefined Antibody Levels for Concomitant Antigen Pertussis, Hepatitis B, Haemophilus Influenzae Type b, Diphtheria, Tetanus and Polio After the 2-Dose Infant Series and After the Toddler Dose Percentage of Participants achieving predefined antibody threshold levels for Pertussis Toxoid (PT) =5 ELISA units per milliliter (EU/mL), Filamentous Haemagglutinin (FHA) =5 or =7.82 EU/mL, and Pertactin (PRN) =5 EU/mL, =10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B, Haemophilus Influenzae type b (Hib) 0.15 µg/ml, 0.01 or 0.1 IU/mL for Diphtheria, 0.1 IU/mL for Tetanus, and =1:8 titer for Polio (Type 1, 2, and 3) with the corresponding 95% CI for antigens are presented. One month after the infant series (6 months of age) and after the toddler dose (12 months of age) No
Primary Geometric Mean Antibody Concentration (GMC) of Pertussis in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose GMC of Pertussis (PT, FHA, PRN) were measured using an anti-Bordetella pertussis enzyme-linked immunosorbent assay (ELISA). Results were recorded in ELISA units per milliliter (EU/mL) one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age) No
Primary Geometric Mean Antibody Concentration (GMC) for Hepatitis B in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After Toddler Dose GMC of anti-hepatitis B surface antigen (HBsAg)using an Food and Drug Administration (FDA) approved in vitro diagnostic kit. One month after the infant series (6 months of age) and the toddler dose (12 months of age) No
Primary Geometric Mean Antibody Concentration (GMC) of Haemophilus Influenzae Type b (Hib) in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose GMC for Hib polyribosylribitol phosphate as measured by ELISA, expressed in micrograms per milliliter (µg/mL). one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age) No
Primary Geometric Mean Antibody Concentration (GMC) of Diptheria and Tetanus in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose GMC of anti-diphtheria and anti-tetanus toxoids as measured by ELISA (IU/mL). one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age) No
Primary Geometric Mean Antibody Concentration (GMC) of Polio Types 1, 2, and 3 in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose GMC of Polio as measured using a polio in vitro plaque neutralization. one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age) No
Primary Percentage of Participants Achieving an Antibody Level of =0.35 µg/mL in the 13vPnC Group After the 2-Dose Infant Series and Before the Toddler Dose Percentages of Participants achieving World Health Organization (WHO) predefined antibody threshold =0.35µg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. one month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age) No
Primary Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the 2-Dose Infant Series and Before Toddler Dose Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age) No
Secondary Percentage of Participants Achieving an Antibody Level of =0.35 µg/mL in the 13vPnC Relative to the 7vPnC Group After the Toddler Dose Percentages of Participants achieving WHO predefined antibody threshold =0.35µg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. One month after the toddler dose (12 months of age) No
Secondary Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Relative to 7vPnC Group After the Toddler Dose Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. One month after toddler dose (12 months of age) No
See also
  Status Clinical Trial Phase
Completed NCT00373958 - Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine Phase 3
Completed NCT00580684 - Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children Phase 4
Completed NCT00366340 - Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants. Phase 3
Completed NCT00366678 - Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants Phase 3
Completed NCT00368966 - Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants. Phase 3
Completed NCT00384059 - Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants Phase 3
Completed NCT00366548 - Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants Phase 3
Completed NCT00444457 - Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants Phase 3
Completed NCT00294294 - Study Evaluating Treatment of Fever in Children Who Have Been Vaccinated With Prevenar and Infanrix Hexa Phase 4
Completed NCT00708682 - Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico Phase 3
Completed NCT00474539 - Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Phase 3
Completed NCT01086397 - Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia N/A